EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma Phosphorylated Tau 217 as a Discriminative Biomarker for Cerebral Amyloid Angiopathy

Pei-Feng Hsieh iD, Hsin-Hsi Tsai iD, Chia-Ju Liu, Bo-Ching Lee iD, Ya-Chin Tsai, Ruoh-Fang Yen, Jiann-Shing Jeng, Li-Kai Tsai

European Journal of Neurology · 2025

DOI: 10.1111/ene.70066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Pei-Feng Hsieh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: tau Proteins, Cerebral Amyloid Angiopathy, Alzheimer Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, National Taiwan University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blood‐based biomarkers may offer a non‐invasive approach to diagnose cerebral amyloid angiopathy (CAA), especially in early‐stage. We evaluated the ability of plasma phosphorylated tau‐217 (p‐tau 217) to differentiate CAA from Alzheimer's disease (AD) and deep perforator arteriopathy (DPA).

Methods

Patients with AD (age 73.7 ± 8.1 years), probable CAA (74.8 ± 6.9 years), or DPA (66.1 ± 10.4 years) were enrolled from memory and stroke clinics at a medical center in Taiwan. All participants received amyloid and tau PET scans. Plasma biomarkers were measured via a SIMOA immunoassay platform. The diagnostic utility of p‐tau 217 was assessed using ROC analyses and the Youden cutoff. Associations between plasma p‐tau 217 and neuroimaging variables in CAA were explored.

Results

Patients with CAA had lower plasma p‐tau 217 (0.69 ± 0.76 vs. 1.28 ± 0.97 pg/mL, p < 0.001) and a lower p‐tau 217/Aβ40 ratio (0.003 ± 0.002 vs. 0.006 ± 0.003, p < 0.001) than the AD group but higher levels than the DPA group (p‐tau 217, 0.27 ± 0.13 pg/mL, p = 0.001; p‐tau 217/Aβ40, 0.001 ± 0.0005, p < 0.001), although adjustment attenuated the difference in p‐tau 217 between CAA and DPA. Plasma Aβ40, Aβ42, and Aβ40/Aβ42 were not significantly different between groups. Plasma p‐tau 217 had moderate to good diagnostic utility to differentiate CAA vs. AD (sensitivity, 64.4%; specificity, 89.5%; AUC, 0.809) and CAA vs. DPA (sensitivity, 67.8%; specificity, 100%; AUC, 0.855). In CAA, p‐tau 217 significantly correlated with the severity of CAA, amyloid PET signal intensity, and lobar microbleed count ( p < 0.001).

Conclusions

Plasma p‐tau 217 may represent a non‐invasive biomarker for distinguishing cerebral amyloid angiopathy (CAA) from other conditions, including AD and DPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsCerebral Amyloid AngiopathyAlzheimer DiseaseHumansAgedFemaleMaleBiomarkersAged, 80 and overPhosphorylationMiddle AgedAmyloid beta-PeptidesDiagnosis, DifferentialPositron-Emission Tomography

Stichwörter der Autor:innen

Alzheimer diseasecerebral amyloid angiopathycerebral small vessel diseasephosphorylated tau 217plasma biomarker

Substanzen

tau ProteinsBiomarkersAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Neurology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.
  • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Nuclear Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.

ORCID-Profile: Pei-Feng Hsieh, Hsin-Hsi Tsai, Bo-Ching Lee

Förderung

  • National Science and Technology Council
  • National Taiwan University Hospital

Zitieren

APA

Hsieh, P. F., Tsai, H. H., Liu, C. J., Lee, B. C., Tsai, Y. C., Yen, R. F., Jeng, J. S., & Tsai, L. K. (2025). Plasma Phosphorylated Tau 217 as a Discriminative Biomarker for Cerebral Amyloid Angiopathy. European Journal of Neurology. https://doi.org/10.1111/ene.70066

Vancouver

Hsieh PF, Tsai HH, Liu CJ, Lee BC, Tsai YC, Yen RF, et al. Plasma Phosphorylated Tau 217 as a Discriminative Biomarker for Cerebral Amyloid Angiopathy. European Journal of Neurology. 2025. doi:10.1111/ene.70066

BibTeX
@article{Hsieh2025,
  author = {Hsieh, Pei-Feng and Tsai, Hsin-Hsi and Liu, Chia-Ju and Lee, Bo-Ching and Tsai, Ya-Chin and Yen, Ruoh-Fang and Jeng, Jiann-Shing and Tsai, Li-Kai},
  title = {Plasma Phosphorylated Tau 217 as a Discriminative Biomarker for Cerebral Amyloid Angiopathy},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70066}
}
Kostenlos starten →